PI-RADS: what is new and how to use it.
Silvina P DutruelSunil JephDaniel J A MargolisNatasha WehrliPublished in: Abdominal radiology (New York) (2021)
The prostate imaging reporting and data system (PI-RADS) has revolutionized the use of magnetic resonance imaging (MRI) for the management of prostate cancer (PCa). The most recent version 2.1, PI-RADS v2.1, provides specific refinements in the performance, relaxing some recommendations which were not found to be helpful, while reinforcing and clarifying others. The interpretation of T2-weighted imaging (T2WI) in the transition zone (TZ), and the overall assessment of TZ nodules, now allows for a clearer distinction between those which are clearly benign and those which might warrant tissue sampling. Additional changes also resolve discrepancies in T2WI and diffusion-weighted imaging (DWI) of the peripheral zone (PZ). PI-RADS v2.1 is a simpler, more straightforward, and more reproducible method to better communicate between physicians regarding findings on prostate MRI.
Keyphrases
- diffusion weighted imaging
- contrast enhanced
- prostate cancer
- magnetic resonance imaging
- diffusion weighted
- radical prostatectomy
- high resolution
- magnetic resonance
- computed tomography
- primary care
- emergency department
- machine learning
- clinical practice
- adverse drug
- fluorescence imaging
- electronic health record
- mass spectrometry